Stephen Spellman

Nov 5, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.

Oct 24, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.

Oct 17, 2024 | nature.com | Niveditha Ravindra |Zoë C Wong |Jeffery J. Auletta |Steven M. Devine |Mark Litzow |Partow Kebriaei | +2 more

To the Editor:High relapse rates for patients despite potentially curative allogeneic hematopoietic cell transplant (alloHCT) remain a critical issue in acute myeloid leukemia (AML). Next-generation sequencing (NGS) represents a promising modality for measurable residual disease (MRD) testing in patients with AML, but the appropriate targets for monitoring must be defined [1,2,3,4,5,6,7].

Oct 17, 2024 | nature.com | Catherine Lee |AKSHAY SHARMA |Taiga Nishihori |Tim Prestidge |Margaret MacMillan |Stephen Spellman | +1 more

AbstractBacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through day 100 post transplant in patients with acute GVHD (AGVHD) based on organ involvement and severity. Patients (n = 4064) who underwent an allogeneic hematopoietic stem cell transplant (HCT) reported to the CIBMTR registry were analyzed.

May 9, 2024 | medrxiv.org | Rodney A. Sparapani |Martin J. Maiers |Stephen Spellman |Bronwen E. Shaw

The authors have declared no competing interest. CIBMTR is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research.